9 Results (Page 1 of 1)
Rare Diseases Free Sample Markets Research Reports
UK Acute Myeloid Leukemia Market Analysis Sample Report
UK Acute Myeloid Leukemia Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The ageing population, higher drug approval rates, the designation of acute myeloid leukaemia as an orphan disease, and rising healthcare costs are anticipated to drive the market. One of the factors accelerating the market's growth is the technological advancement made possible by the capacity to recognise damaged cells. Major global players in Acute Myeloid Leukemia Market are Ambit Biosciences Corporation, Genzyme Corporation, Celgene Corporation, Clavis Pharma ASA, Sunesis Pharmaceuticals, Cephalon, Bristol-Myers Squibb, Novartis International AG, GlaxoSmithKline.
Global Cholangiocarcinoma Market Analysis Sample Report
The Global Cholangiocarcinoma market is expected to witness growth as the incidence of Cholangiocarcinoma is rising globally. The market is segmented by treatments, distribution channels, and regions. Incyte Corporation and Eisai are the key players in the Global Cholangiocarcinoma market.
India Multiple Myeloma Market Analysis Sample Report
The India multiple myeloma market is projected to grow as a result of the increasing prevalence of hematological cancers in India. The market is segmented by disease type, treatment type, diagnosis, dosage form, route of administration, end users and by distribution channel.
Australia Primary Hyperoxaluria (PH) Market Analysis Sample Report
Australia Primary Hyperoxaluria (PH) market stood at around $2.1 Mn in 2022 and is projected to reach $8.8 Mn with a CAGR of 19% for the year 2022-2030. The market is segmented by type, diagnosis, drug, treatment and by distribution channel. Alnylam Pharmaceuticals and Dicerna Pharmaceuticals are some of the key players in the Australia PH market.
Australia Sickle Cell Disease Market Analysis Sample Report
Australia Sickle Cell Disease market is expected to grow from $1.1 Mn in 2022 to $2.6 Mn in 2030 with a CAGR of 11% for the year 2022 to 2030. The market is segmented by treatment modality and by distribution channel. Novartis and AstraZeneca are some of the key players in the Australia sickle cell disease market.
Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Drugs Market Analysis Sample Report
The introduction of new therapeutic options for the acute phase of NMOSD presents a potential opportunity for the growth of the Global NMOSD drugs market. The market is segmented by drug therapy, application, distribution channel, and by region. Novartis and Pfizer are the key players in the market.
China Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics Market Sample Report
China Paroxysmal Nocturnal Hemoglobinuria (PNH) therapeutics market is growing due to the increased cases of PNH cases in China. Although being a rare disease, its prevalence in China and the increased adoption of novel therapeutics to treat PNH are the major market drivers of the China PNH therapeutics market.
US Acute Myeloid Leukemia Market Analysis Sample Report
US Acute Myeloid Leukemia Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023-30. The ageing population, higher drug approval rates, the designation of acute myeloid leukaemia as an orphan disease, and rising healthcare costs are anticipated to drive the market. One of the factors accelerating the market's growth is the technological advancement made possible by the capacity to recognise damaged cells. Major global players in Acute Myeloid Leukemia Market are Ambit Biosciences Corporation, Genzyme Corporation, Celgene Corporation, Clavis Pharma ASA, Sunesis Pharmaceuticals, Cephalon, Bristol-Myers Squibb, Novartis International AG, GlaxoSmithKline.
Egypt Myasthenia Gravis Drugs Market Analysis Sample Report
Egypt Myasthenia Gravis Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. The market for myasthenia gravis is rising due to increasing prevalence and incidence of disease, improved diagnostic techniques, increased awareness and better understanding of the disease, Supportive Government Initiatives like providing financial support, improving healthcare infrastructure, promoting research in rare diseases and Technological Advancements in drugs and therapies treating myasthenia gravis. Major global players in Myasthenia Gravis Drugs Market are Alexion Pharmaceuticals, Inc., Bausch Health Companies, Inc., Novartis AG, Amneal Pharmaceuticals LLC, Zydus Cadila, Avadel, Dr. Reddy's Laboratories, Ltd., Fresenius Kabi, AG, Endo Pharmaceuticals, Inc., Amphastar Pharmaceuticals, Inc., Mylan N.V., Aurobindo Pharma, Pfizer, Inc., Astellas Pharma, Inc.
